Convalescent Plasma

Health ministry recommends tocilizumab, HCQ, plasma therapy for patients in the moderate stage of COVID-19

HCQ has demonstrated in-vitro activity against SARS-CoV-2 and shown to be clinically beneficial in several small single-centre studies with significant limitations.

Unregulated use of plasma therapy for COVID-19 can be harmful, writes expert; can expose patients to serious transfusion-related risks

It is a promising solution at the present gloomy situation, but till we have reliable evidence on utility unregulated use is to be avoided

Phase 3 results on Gilead coronavirus drug encouraging; a look at other potential COVID-19 treatments under trial

California-based biotech company Gilead Sciences and the US government reported that in a major study, remdesivir shortened the time it takes for COVID-19 patients to recover by four days on average

Several antiviral drugs to treat the coronavirus outbreak under clinical trials, shown good efficacy: Chinese official

Hospitals are using plasma from recovered patients, that is rich in protective antibodies, to treat severely affected patients.